Equities

Scisparc Ltd

SPRC:NAQ

Scisparc Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2423
  • Today's Change-0.003 / -1.22%
  • Shares traded12.85k
  • 1 Year change-97.59%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

  • Revenue in USD (TTM)0.00
  • Net income in USD-6.96m
  • Incorporated2004
  • Employees3.00
  • Location
    Scisparc Ltd20 Raul Wallenberg Street, Tower ATEL AVIV-YAFO 6971916IsraelISR
  • Phone+972 36103100
  • Fax+972 36167056
  • Websitehttps://scisparc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
60 Degrees Pharmaceuticals Inc462.61k-8.39m1.68m3.00------3.62-9.19-9.190.38673.240.05580.78632.00154,203.30-95.99---123.36--10.73---1,719.15--4.91--0.0256---50.40--35.51------
cbdMD Inc20.64m-23.42m1.73m52.00--0.5845--0.084-18.95-18.957.850.80550.88172.0120.35396,856.90-82.98-38.59-112.36-41.5063.4363.80-94.12-87.980.5172-3.890.3128---31.77120.9163.64---4.95--
PainReform Ltd0.00-17.67m1.75m6.00---------167.66-167.660.00-14.120.00----0.00-309.43-55.47-650.22-68.20---------------------6.28------
SOHM Inc-100.00bn-100.00bn1.82m--------------------------------------------------------------
InVitro International716.89k6.22k1.82m16.00228.572.49--2.540.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
Panacea Life Sciences Holdings Inc2.76m-7.67m2.08m40.00------0.7511-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.124.79--46.59--12.33------
Lotus Pharmaceuticals Inc70.79m1.72m2.16m233.000.01450.00020.55860.03050.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Scisparc Ltd0.00-6.96m2.54m3.00--7.05-----1.22-1.510.000.03440.00----0.00-92.51-69.39-152.41-111.07-------527.17----0.9371--113.73---97.61------
CYANOTECH CORP23.30m-5.45m2.72m77.00--0.2510--0.1167-0.7939-0.79393.401.360.8962.1515.42302,532.50-20.98-3.46-32.30-4.4622.6634.54-23.41-3.580.307-7.000.42---0.4616-5.24-53.11---6.42--
Psyence Biomedical Ltd0.001.52m2.76m------1.82---0.0442-0.04420.00-0.39790.00------1.13--1.20-----------------------2.63------
Processa Pharmaceuticals Inc0.00-11.53m2.81m13.00--0.8587-----4.86-4.860.001.140.00----0.00-176.99-84.35-209.96-90.03------------0.0022------59.45---34.05--
Scorpius Holdings Inc10.04m-29.66m2.86m82.00--0.0812--0.2846-107.62-101.175.258.120.1725--16.55122,491.30-53.23-39.37-69.92-43.1861.92---308.58-1,068.210.6007-27.310.3146--1,789.583.841.96--27.32--
Universe Pharmaceuticals Inc26.73m-18.55m3.04m225.00--0.0169--0.1138-76.44-76.44110.26110.020.44626.131.68118,781.90-30.975.31-48.857.0728.2746.26-69.406.251.46-0.69390.19580.00-19.522.5329.46---21.17--
NovaBay Pharmaceuticals Inc11.20m-16.44m3.33m24.00--2.85--0.2971-53.22-53.407.770.21951.342.2213.83466,625.00-119.49-61.51-196.48-83.8960.6759.99-89.25-86.470.9103--0.0454--2.243.32-2.66---15.46--
Titan Pharmaceuticals Inc4.00k-5.46m3.39m4.00--0.8782--847.95-6.59-6.590.00494.370.0016--0.17021,000.00-211.58-96.80-368.99-156.65-----136,525.00-406.26---309.960.00---66.97-51.1645.43---65.61--
Data as of Nov 25 2024. Currency figures normalised to Scisparc Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.73%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 30 Sep 202469.01k0.67%
Yorkville Advisors Global LPas of 27 Feb 202455.29k0.53%
Two Sigma Securities LLCas of 30 Sep 202437.08k0.36%
Virtu Americas LLCas of 30 Sep 202414.11k0.14%
RhumbLine Advisers LPas of 30 Sep 20243.46k0.03%
Morgan Stanley & Co. LLCas of 30 Sep 2024233.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 20245.000.00%
Two Sigma Investments LPas of 30 Sep 20240.000.00%
Renaissance Technologies LLCas of 30 Sep 20240.000.00%
Citadel Securities LLCas of 30 Sep 20240.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.